贵阳朗玛信息技术股份有限公司（以下简称"公司"）董事会于近日收到 王健先生的辞职报告，公司董事、总经理王健先生因个人原因申请辞去公司第 五届董事会董事及董事会战略委员会委员职务，辞去前述职务后，王健先生继 续担任公司总经理职务。 王健先生担任公司董事的原定任期至第五届董事会任期届满之日止（2026 年3月9日）。根据相关法律、法规及《公司章程》的规定，王健先生辞去董事 职务将导致公司董事会人数低于法定最低人数，其辞职报告自补选董事任职后 生效，为保证董事会的正常运行，在补选董事就任前，王健先生将继续按法律、 法规和《公司章程》的规定履行董事职责。 截至本公告披露日，王健先生未直接持有公司股份，其配偶及其他关联人 未持有公司股票，不存在应当履行而未履行的承诺事项。 王健先生在公司担任董事期间，恪尽职守、勤勉尽责，公司及董事会对王 健先生为公司发展做出的贡献表示高度认可和衷心感谢！ 证券代码：300288 证券简称：朗玛信息 公告编号：2024-017 贵阳朗玛信息技术股份有限公司 关于董事辞职暨补选非独立董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 ...

贵阳朗玛信息技术股份有限公司 2023 年度监事会工作报告 2023 年，贵阳朗玛信息技术股份有限公司（以下简称"公司"）监事会全 体成员严格按照《公司法》《证券法》等法律、法规及《公司章程》《监事会议 事规则》有关规定，本着对全体股东负责的精神，认真切实地履行了自身职责， 依法独立行使职权，维护公司、股东及员工的合法权益。 报告期内，公司监事列席了 2023 年董事会会议、股东大会，对公司的财务 状况、股东大会决议执行情况、董事会的重大决策程序及公司经营管理活动的合 法合规性、董事及高级管理人员履职情况等方面进行了监督和检查，以保障公司 健康、持续、稳定的发展。现将监事会 2023 年主要工作情况报告如下： 一、监事会会议召开情况 报告期内，监事会共召开 5 次会议，会议情况如下： | 序 | 召开时间 | 会议名称 | 议案 | | --- | --- | --- | --- | | 号 | | | | | 1 | 2023年2月 | 第四届监事会 | 审议通过了《关于公司监事会换届选举暨提名第五届监 | | | 20日 | 第十四次会议 | 事会非职工代表监事候选人的议案》 | | 2 | 2023年3 ...

贵阳朗玛信息技术股份有限公司董事会 关于独立董事独立性评估的专项意见 因此，公司在任独立董事陈文德先生、杨小舟先生符合《上市公司独立董事 管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》中对独立董事独立性的相关要求。 贵阳朗玛信息技术股份有限公司董事会 2024 年 4 月 22 日 贵阳朗玛信息技术股份有限公司（以下简称"公司"）董事会根据《上市公 司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等要求，就公司在 任独立董事陈文德先生、杨小舟先生的独立性情况进行评估并出具如下专项意见： 经核查，公司在任独立董事陈文德先生、杨小舟先生的任职经历以及签署的 相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司 主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可 能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况。 ...

二、内部控制评价结论 （一）公司于内部控制评价报告基准日，是否存在财务报告内部控制重大缺陷 □是 否 贵阳朗玛信息技术股份有限公司 2023 年度内部控制自我评价报告 贵阳朗玛信息技术股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合贵阳朗玛信息技术股份有限公 司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司 2023 年 12 月 31 日（内部控制评价报告基准日）的内 部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导公司内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率 ...

Financial Performance - The company's operating revenue for 2023 reached CNY 459,582,706, representing a year-on-year increase of 5.26% compared to CNY 436,617,213 in 2022[21]. - The net profit attributable to shareholders for 2023 was CNY 77,457,117, marking a 10.19% increase from CNY 70,288,596 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 74,144,969, which is a 10.04% increase from CNY 67,369,279 in 2022[21]. - The net cash flow from operating activities for 2023 was CNY 87,075,703, reflecting a significant increase of 17.67% compared to CNY 73,999,859 in 2022[21]. - The basic earnings per share for 2023 increased to CNY 0.23, up 9.52% from CNY 0.21 in 2022[22]. - Total assets at the end of 2023 reached CNY 1,882,211,378, representing a 1.78% increase from CNY 1,849,235,200 in 2022[22]. - The net assets attributable to shareholders increased by 5.07% to CNY 1,611,374,700 at the end of 2023, compared to CNY 1,533,587,100 in 2022[22]. - The weighted average return on equity for 2023 was 4.93%, an increase of 0.26% from 4.67% in 2022[22]. Market and Business Development - The company continues to explore market expansion opportunities, particularly in the internet healthcare sector[15]. - The company has developed a comprehensive "Internet + Healthcare" ecosystem, integrating online medical services with offline hospitals[42]. - The internet medical user base grew to 431 million in the first half of 2023, a year-on-year increase of 18.73%[35]. - The projected market size for internet medical services in 2023 is CNY 385.4 billion, reflecting a 24.25% year-on-year growth[35]. - The company is focusing on the development of medical artificial intelligence and expanding its internet healthcare services[42]. - The company aims to connect high-quality medical resources to grassroots healthcare through remote medical services and training[48]. - The company is addressing external competition and regulatory changes while focusing on achieving profitability in its internet healthcare business[108]. - The company plans to promote its internet healthcare services in grassroots medical institutions, aiming to provide standardized quality healthcare services[108]. Research and Development - The company is focusing on the development of its AI-powered product "39AI General Practitioner," which aims to enhance medical consultation and clinical diagnosis[107]. - Research and development expenses increased by 30% in 2023, focusing on AI and big data technologies[139]. - The number of R&D personnel increased to 137 in 2023, up from 123 in 2022, representing a growth of 11.38%[86]. - The proportion of R&D personnel in the company rose to 15.68% in 2023, compared to 13.49% in 2022, an increase of 2.19%[86]. - The company has successfully developed a medical health consultation dialogue robot using large language model technology, addressing traditional medical consultation service challenges[86]. Governance and Compliance - The company has established a comprehensive internal audit system to ensure the authenticity and completeness of financial information[121]. - The governance structure complies with relevant laws and regulations, with a board consisting of 5 members, including 2 independent directors[119]. - The company has implemented a performance evaluation and incentive system for senior management, ensuring transparency in hiring processes[120]. - The board of directors has not raised any objections regarding company matters during the reporting period[148]. - The company has not faced any administrative penalties due to environmental issues during the reporting period, adhering to various environmental protection laws[170]. Shareholder Engagement and Dividends - The company plans to distribute a cash dividend of CNY 0.45 per 10 shares, based on a total of 337,941,402 shares[4]. - The company did not distribute cash dividends for the 2022 fiscal year, citing the need for significant capital investment in artificial intelligence technology development[158]. - The company emphasizes a competitive compensation policy, including performance bonuses and stock incentive plans to enhance employee motivation[153]. - The company is committed to enhancing shareholder engagement through regular meetings and transparent communication[125]. Operational Efficiency and Cost Management - The company aims to reduce operational costs by 10% through efficiency improvements in the next fiscal year[139]. - The management team emphasizes a commitment to operational efficiency and cost management to enhance profitability[1]. - The total operating costs for the IPTV and telephone services were CNY 1,627,584.84, with a gross margin of 84.59%[73]. - The total operating costs for the mobile resale business were CNY 82,920,525.50, with a gross margin of 40.21%[74]. - The medical services segment's total operating costs were CNY 177,949,851.75, reflecting a 10.51% increase year-on-year[74]. Future Outlook - Future guidance indicates a positive outlook, with strategic initiatives aimed at increasing market share and operational efficiency[134]. - The company plans to continue its strategic acquisitions to bolster its competitive position in the industry[1]. - Future performance guidance indicates a projected revenue growth of approximately 15% year-over-year for 2024[1]. - The company aims to enhance its talent pool to support strategic activities in technology research, market competition, and management innovation[109].

作为贵阳朗玛信息技术股份有限公司（以下简称"公司"）第四届董事会的独 立董事，2023年度任期内（2023年1月1日-2023年3月10日），本人严格按照《公司 法》《上市公司独立董事规则》《深圳证券交易所上市公司自律监管指引第2号— —创业板上市公司规范运作（2023年修订）》等相关法律、法规、规范性文件及《公 司章程》《独立董事工作制度》等有关规定，认真行使公司赋予的权利，及时了解 公司的经营信息，全面关注公司的发展状况，积极出席公司召开的相关会议，对公 司董事会审议的相关事项发表了独立客观的意见，忠实履行职责，监督公司规范化 运作，充分发挥独立董事的独立作用，维护了全体股东尤其是中小股东的合法权益。 现将2023年度本人任职期间履行独立董事职责的工作情况报告如下： 一、 基本情况 贵阳朗玛信息技术股份有限公司 2023 年度独立董事述职报告 （刘景伟） 二、独立董事年度履职概况 （一）出席董事会及股东大会的情况 本年度任期内，本着勤勉尽责的态度，本人均按时出席召开的董事会和股东 大会，认真审阅会议资料，参与各议题的讨论并提出合理建议，为董事会的正确决 策发挥了积极作用。公司董事会、股东大会的召集、召开符 ...

贵阳朗玛信息技术股份有限公司 2023 年度独立董事述职报告 （陈文德） 作为贵阳朗玛信息技术股份有限公司（以下简称"公司"）第五届董事会的独 立董事，2023年度任期内（2023年3月10日-2023年12月31日），本人严格按照《公 司法》《证券法》《深圳证券交易所创业板股票上市规则》等相关法律法规、规范 性文件及《公司章程》《独立董事工作制度》等有关规定，认真行使公司赋予的权 利，及时了解公司的经营信息，全面关注公司的发展状况，积极出席公司召开的相 关会议，对公司董事会审议的相关事项发表了独立客观的意见，忠实履行职责，监 督公司规范化运作，充分发挥独立董事的独立作用，维护了全体股东尤其是中小股 东的合法权益。现将2023年度本人任职期间履行独立董事职责的工作情况报告如下： 一、基本情况 （一）工作履历、专业背景及兼职情况 本人陈文德，1963年出生，中国国籍，无境外永久居留权，硕士学历。2023 年12月29日至今任江苏亚虹医药科技股份有限公司董事，2023年3月至今任公司独 立董事。 （二）独立性说明 在担任公司独立董事期间，本人未在公司担任除独立董事、董事会专门委员 会委员以外的任何职务，也未在公司 ...

贵阳朗玛信息技术股份有限公司 未来三年（2024-2026年）股东回报规划 为进一步完善贵阳朗玛信息技术股份有限公司（以下简称"公司"）利润分 配决策和监督机制，增强公司利润分配的透明度，持续、稳定、科学地回报投资 者，引导投资者树立长期投资和理性投资理念，公司根据《关于进一步落实上市 公司现金分红有关事项的通知》《上市公司监管指引第 3 号——上市公司现金分 红（2023 年修订）》及《公司章程》等有关规定，结合公司实际情况，特制定未 来三年（2024-2026 年）股东回报规划（以下简称"本规划"），具体内容如下： 一、本规划制定的基本原则 公司的利润分配应重视对投资者的合理投资回报并兼顾公司的持续经营，执 行连续、稳定的利润分配原则；每年按当年实现的合并报表可供分配利润规定比 例向股东分配股利；公司的利润分配政策保持连续性和稳定性，同时兼顾公司的 长远利益、全体股东的整体利益及公司的可持续发展。公司未来三年（2024-2026 年）将在符合相关法律法规及《公司章程》的前提下，充分考虑公司股东的要求 和意愿，利润分配以现金分红为主，持续、稳定、科学地回报投资者。 二、本规划考虑的因素 本规划着眼于公司的长 ...

Financial Performance - The company's revenue for Q1 2024 was ¥79,459,636.01, representing a decrease of 25.48% compared to ¥106,621,778.87 in the same period last year[6] - Net profit attributable to shareholders decreased by 70.28% to ¥6,320,115.93 from ¥21,263,432.84 year-on-year[6] - Basic and diluted earnings per share fell by 70.27% to ¥0.0187 from ¥0.0629 year-on-year[6] - Net profit for Q1 2024 was CNY 5,465,039.19, a decline of 73.6% from CNY 20,681,420.89 in Q1 2023[26] - Total comprehensive income for Q1 2024 was CNY 5,465,039.19, a decrease of 73.6% compared to CNY 20,681,420.89 in Q1 2023[26] Cash Flow - The net cash flow from operating activities dropped significantly by 88.81%, down to ¥1,177,013.52 from ¥10,517,895.97 in the previous year[6] - Cash flow from operating activities generated a net amount of CNY 1,177,013.52, significantly lower than CNY 10,517,895.97 in Q1 2023[28] - The net cash flow from investment activities was -1,285,057.18 CNY for Q1 2024, compared to -6,219,657.75 CNY in the same period last year[29] - The net cash flow from financing activities was -14,350,583.33 CNY in Q1 2024, compared to -668,376.39 CNY in Q1 2023[29] - The net increase in cash and cash equivalents was -14,458,626.99 CNY for Q1 2024, while it was 3,629,861.83 CNY in Q1 2023[29] - The ending balance of cash and cash equivalents was 286,895,774.33 CNY at the end of Q1 2024, down from 335,159,684.00 CNY at the end of Q1 2023[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,884,066,654.18, a slight increase of 0.10% from ¥1,882,211,378.44 at the end of the previous year[6] - The company reported a total asset of CNY 1,884,066,654.18 as of March 31, 2024, compared to CNY 1,882,211,378.44 at the beginning of the period, showing a slight increase[19] - Total liabilities decreased to CNY 241,625,042.97 from CNY 245,234,806.42, a reduction of 1.5%[25] - The total current liabilities increased, with accounts payable rising to CNY 131,854,299.59 from CNY 116,147,425.72, marking an increase of about 13.5%[21] - The company’s inventory decreased to CNY 8,441,465.06 from CNY 9,045,369.30, reflecting a decline of approximately 6.7%[20] Expenses - Research and development expenses increased by 118.92% compared to the same period last year, indicating a significant investment in innovation[12] - Sales expenses decreased by 39.82%, primarily due to reduced business expenses at a subsidiary[12] - Total operating costs for Q1 2024 were CNY 77,159,993.40, down 13.9% from CNY 89,587,852.81 year-over-year[25] - Research and development expenses increased to CNY 11,102,265.54, up 118.9% from CNY 5,071,479.88 in the same quarter last year[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 48,420[14] - The largest shareholder, Wang Wei, holds 32.10% of the shares, totaling 108,496,015 shares[14] - Total equity attributable to shareholders of the parent company was CNY 1,617,694,864.47, slightly up from CNY 1,611,374,748.54[25] Regulatory and Product Developments - The company has been recognized as a high-tech enterprise, allowing it to benefit from a reduced corporate income tax rate of 15% from 2023 to 2025[16] - The "39AI General Practitioner" model was officially launched on March 1, 2024, aimed at providing medical consultation and assisting primary care physicians[17] - The company’s "39 Health Medical Content Generation Algorithm" received regulatory approval on February 18, 2024, enhancing its AI capabilities[17] Accounting and Audit - The company did not undergo an audit for the Q1 2024 report[31] - The report indicates that the company will implement new accounting standards starting in 2024[30]

贵阳朗玛信息技术股份有限公司 2023年度财务决算报告 贵阳朗玛信息技术股份有限公司（以下简称"公司"）2023 年 12 月 31 日 资产负债表、2023 年度利润表、2023 年度现金流量表、2023 年度股东权益变动 表及相关报表附注已经大华会计师事务所（特殊普通合伙）审计，并出具标准 无保留意见的审计报告。 | 项目 | 2023 年 | 2022 年 | 本年比上年增减 | | --- | --- | --- | --- | | 营业总收入 | 459,582,706.22 | 436,617,213.15 | 5.26% | | 营业利润 | 90,188,889.81 | 81,354,396.36 | 10.86% | | 利润总额 | 90,022,809.18 | 80,076,230.10 | 12.42% | | 归属于上市公司股东的净 利润 | 77,457,117.42 | 70,296,299.37 | 10.19% | | 经营活动产生的现金流量 | 87,075,703.27 | 73,999,859.23 | 17.67% | | 净额 | | | | | 资产总额 | ...